Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: pregnant (230), expectant (11)

Annual complaints report 2020-21

Description: ANNUAL COMPLAINTS REPORT 2020/21 RETROSPECTIVE PERFORMANCE LOOKING FORWARDS “All patients, from every background and walk of life, will experience the
Url: /Media/UHS-website-2019/Patientinformation/Contactingus/Annual-complaints-report-2020-21.pdf

Durvalumab(28day-1500mg)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indication • Durvalumab is
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

Atezolizumab1680mg

Description: Chemotherapy Protocol LUNG CANCER Atezolizumab (1680mg 28 days) Regimen • Lung – Atezolizumab Indication • Atezolizumab is indicated for treating previously platinum-treated locally
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Atezolizumab1680mg.pdf

Atezolizumab

Description: Chemotherapy Protocol LUNG CANCER Atezolizumab Regimen • Lung – Atezolizumab Indication • Atezolizumab is indicated for treating previously platinum-treated locally advanced/ metastatic non
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Atezolizumab.pdf

Pembrolizumab 400mg (bladder)

Description: Chemotherapy Protocol BLADDER CANCER Pembrolizumab (400mg) Regimen • Bladder – Pembrolizumab (400mg) Indication • Pembrolizumab is indicated for locally advanced (ie T4b any N
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Pembrolizumab-400mg.pdf

Pembrolizumab 200mg (bladder)

Description: Chemotherapy Protocol BLADDER CANCER Pembrolizumab (200mg) Regimen • Bladder – Pembrolizumab (200mg) Indication • Pembrolizumab is indicated for locally advanced (ie T4b any N
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Pembrolizumab-200mg.pdf

Tivozanib

Description: Chemotherapy Protocol RENAL CELL Regimen TIVOZANIB • Renal Cell - Tivozanib Indication • Patients with a confirmed histological diagnosis of renal cell carcinoma with
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Tivozanib.pdf

Ipilimumab(1mg/kg)-Nivolumab(3mg/kg)

Description: Chemotherapy Protocol RENAL CANCER IPILIMUMAB (1mg/kg)-NIVOLUMAB(3mg/kg) Regimen • Renal – Ipilimumab (1mg/kg)-Nivolumab (3mg/kg) Indication • Ipilimumab in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Ipilimumab1mgkg-Nivolumab3mgkg.pdf

Everolimus-Lenvatinib

Description: Chemotherapy Protocol RENAL CELL EVEROLIMUS and LENVATINIB Regimen • Renal Cell – Everolimus-Lenvatinib Indication • Confirmed histological diagnosis of inoperable locally advanced or
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Everolimus-Lenvatinib.pdf

Bendamustine-Polatuzumab-Rituximab

Description: Chemotherapy Protocol LYMPHOMA BENDAMUSTINE-POLATUZUMAB-RITUXIMAB Regimen • Lymphoma – Bendamustine-Polatuzumab-Rituximab Indication • Histologically diagnosed diffuse large B cell lymphoma (DLBCL) including
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bendamustine-Polatuzumab-Rituximab.pdf

581 to 590 of 634

Previous … 57 58 59 60 61 … Next